Jeffrey Ives

Jeffrey Ives

Director/Board Member at ACUMEN PHARMACEUTICALS, INC.

Net worth: 36 480 $ as of 2026-08-30

75 year
Health Technology
Consumer Services
Finance

Profile

Jeffrey L.
Ives
is currently Independent Director at Acumen Pharmaceuticals, Inc. since 2014, Director at Astrocyte Pharmaceuticals, Inc. since 2014, and Principal at Neuropharma Advisors LLC since 2013.
Former positions include Chief Executive Officer & Director at Satori Pharmaceuticals, Inc. from 2009 to 2013, Director & Vice President-Business Development at Celgene Corp., Independent Director at CARA Therapeutics, Inc., Director at Pinteon Therapeutics, Inc., Director at Orthogonal Neuroscience (US), Inc., Senior Vice President at Pfizer Inc. from 2001 to 2007, Executive-in-Residence at PureTech Health LLC, Senior Vice President-Research Portfolio at Pfizer (St. Louis) from 2001 to 2007, and Venture Partner at New Leaf Venture Partners LLC from 2017 to 2021.
Education includes undergraduate studies at Colgate University and graduate and doctorate degrees from Yale University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-06-02 12,800 ( 0.02% ) 36 480 $ 2026-08-30

Jeffrey Ives active positions

CompaniesPositionStart
ACUMEN PHARMACEUTICALS, INC. Director/Board Member 2014-04-30
Neuropharma Advisors LLC
Corporate Officer/Principal 2013-08-31
Director/Board Member 2014-11-30

Former positions of Jeffrey Ives

CompaniesPositionEnd
Private Equity Investor 2021-02-28
Chief Executive Officer 2012-12-31
Corporate Officer/Principal 2006-12-31
PFIZER INC. Corporate Officer/Principal 2006-12-31
See the detail of Jeffrey Ives's experience

Training of Jeffrey Ives

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

87

1st degree connections

13

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies13

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Finance

Finance

Health Technology

Neuropharma Advisors LLC

Health Technology

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!